Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024 07:00 ET
|
Viracta Therapeutics, Inc.
- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to...
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
November 06, 2024 16:30 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 07:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 07:05 ET
|
Viracta Therapeutics, Inc.
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val’s substantial...
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
August 14, 2024 07:00 ET
|
Viracta Therapeutics, Inc.
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val’s substantial...
Viracta Therapeutics Announces New Employment Inducement Grants
May 17, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
May 14, 2024 07:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell...
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 07, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
April 15, 2024 08:00 ET
|
Viracta Therapeutics, Inc.
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete...